Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Moleculin Biotech, Inc. (MBRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4700+0.0200 (+1.38%)
At close: 04:00PM EDT
1.5900 +0.12 (+8.16%)
After hours: 04:20PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close1.4500
Open1.4200
Bid1.4700 x 1400
Ask1.5900 x 900
Day's Range1.4200 - 1.5300
52 Week Range1.0200 - 3.7400
Volume22,615
Avg. Volume71,755
Market Cap42.01M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-0.6410
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.39
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MBRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Moleculin Biotech, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, Skyworks soars, Big Biopharma builds immunity to headwinds, and Baidu and the cloud; and Harmonic Drive Systems, Elekta, and Nabtesco.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • PR Newswire

    Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported preliminary results from the first cohort of the Company's first-in-human Phase 1a study of WP1122. This cohort consisted of 9 subjects dosed with 8 mg/kg or placebo in the dose escalation trial evaluating the safety and pharmacokinetics (PK) of WP1122 in healthy volunteers in the Un

  • PR Newswire

    Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the commencement of dosing in its first-in-human Phase 1a study to evaluate the safety and pharmacokinetics (PK) of WP1122 in healthy volunteers for the treatment of COVID-19 (MB-301). WP1122, the Company's lead metabolism/glycosylation inhibitor, is a prodrug of a well-known glucos

  • PR Newswire

    Moleculin to Present at the H.C. Wainwright Global Investment Conference

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

Advertisement
Advertisement